The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis - PubMed (original) (raw)
Multicenter Study
doi: 10.1002/hep.28414. Epub 2016 Feb 19.
K Rajender Reddy 2, Puneeta Tandon 3, Florence Wong 4, Patrick S Kamath 5, Guadalupe Garcia-Tsao 6, Benedict Maliakkal 7, Scott W Biggins 8, Paul J Thuluvath 9, Michael B Fallon 10, Ram M Subramanian 11, Hugo Vargas 12, Leroy R Thacker 1, Jacqueline G O'Leary 13; North American Consortium for the Study of End-Stage Liver Disease
Affiliations
- PMID: 26690389
- PMCID: PMC4700508
- DOI: 10.1002/hep.28414
Multicenter Study
The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis
Jasmohan S Bajaj et al. Hepatology. 2016 Jul.
Abstract
In smaller single-center studies, patients with cirrhosis are at a high readmission risk, but a multicenter perspective study is lacking. We evaluated the determinants of 3-month readmissions among inpatients with cirrhosis using the prospective 14-center North American Consortium for the Study of End-Stage Liver Disease cohort. Patients with cirrhosis hospitalized for nonelective indications provided consent and were followed for 3 months postdischarge. The number of 3-month readmissions and their determinants on index admission and discharge were calculated. We used multivariable logistic regression for all readmissions and for hepatic encephalopathy (HE), renal/metabolic, and infection-related readmissions. A score was developed using admission/discharge variables for the total sample, which was validated on a random half of the total population. Of the 1353 patients enrolled, 1177 were eligible on discharge and 1013 had 3-month outcomes. Readmissions occurred in 53% (n = 535; 316 with one, 219 with two or more), with consistent rates across sites. The leading causes were liver-related (n = 333; HE, renal/metabolic, and infections). Patients with cirrhosis and with worse Model for End-Stage Liver Disease score or diabetes, those taking prophylactic antibiotics, and those with prior HE were more likely to be readmitted. The admission model included Model for End-Stage Liver Disease and diabetes (c-statistic = 0.64, after split-validation 0.65). The discharge model included Model for End-Stage Liver Disease, proton pump inhibitor use, and lower length of stay (c-statistic = 0.65, after split-validation 0.70). Thirty percent of readmissions could not be predicted. Patients with liver-related readmissions consistently had index-stay nosocomial infections as a predictor for HE, renal/metabolic, and infection-associated readmissions (odds ratio = 1.9-3.0).
Conclusions: Three-month readmissions occurred in about half of discharged patients with cirrhosis, which were associated with cirrhosis severity, diabetes, and nosocomial infections; close monitoring of patients with advanced cirrhosis and prevention of nosocomial infections could reduce this burden. (Hepatology 2016;64:200-208).
© 2015 by the American Association for the Study of Liver Diseases.
Figures
Figure 1
Flow of patients through the study.
Figure 2
Proportion of subjects who were re-admitted in 3-months based on reason for index admission. No statistically significant difference was found (p=0.60). HE: hepatic encephalopathy, Renal/Met: renal or metabolic etiology
Comment in
- Challenge accepted: Confronting readmissions for our patients with cirrhosis.
Tapper EB. Tapper EB. Hepatology. 2016 Jul;64(1):26-8. doi: 10.1002/hep.28471. Epub 2016 Mar 15. Hepatology. 2016. PMID: 26806609 No abstract available.
Similar articles
- Hospital readmissions among patients with decompensated cirrhosis.
Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Volk ML, et al. Am J Gastroenterol. 2012 Feb;107(2):247-52. doi: 10.1038/ajg.2011.314. Epub 2011 Sep 20. Am J Gastroenterol. 2012. PMID: 21931378 Free PMC article. - Risk Factors for 30-Day Readmissions of Individuals with Decompensated Cirrhosis.
Agrawal K, Kumar P, Markert R, Agrawal S. Agrawal K, et al. South Med J. 2015 Nov;108(11):682-7. doi: 10.14423/SMJ.0000000000000371. South Med J. 2015. PMID: 26539950 - Predictors of 1-month and 3-months Hospital Readmissions in Decompensated Cirrhosis: A Prospective Study in a Large Asian Cohort.
Patel R, Poddar P, Choksi D, Pandey V, Ingle M, Khairnar H, Sawant P. Patel R, et al. Ann Hepatol. 2019 Jan-Feb;18(1):30-39. doi: 10.5604/01.3001.0012.7859. Ann Hepatol. 2019. PMID: 31113606 - Strategies to Reduce Hospital Readmissions.
Chirapongsathorn S, Talwalkar JA, Kamath PS. Chirapongsathorn S, et al. Semin Liver Dis. 2016 May;36(2):161-6. doi: 10.1055/s-0036-1583196. Epub 2016 May 12. Semin Liver Dis. 2016. PMID: 27172358 Review. - The Burden of Rehospitalization for Patients With Liver Cirrhosis.
Desai AP, Reau N. Desai AP, et al. Hosp Pract (1995). 2016;44(1):60-9. doi: 10.1080/21548331.2016.1142828. Epub 2016 Feb 3. Hosp Pract (1995). 2016. PMID: 26782133 Review.
Cited by
- Hospital Utilization for Patients With Cirrhosis and Severe Ascites in a Model of Outpatient Paracentesis by Interventional Radiology.
Ahmed M, Islam M, Gogokhia L, Borz-Baba C, Wakefield D, Jakab SS. Ahmed M, et al. Cureus. 2023 Dec 31;15(12):e51397. doi: 10.7759/cureus.51397. eCollection 2023 Dec. Cureus. 2023. PMID: 38292997 Free PMC article. - Long-Term Mortality and Hospital Resource Use in ICU Patients With Alcohol-Related Liver Disease.
Lone NI, Lee R, Walsh TS. Lone NI, et al. Crit Care Med. 2019 Jan;47(1):23-32. doi: 10.1097/CCM.0000000000003421. Crit Care Med. 2019. PMID: 30247272 Free PMC article. - Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.
Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, Fagan A, Hayward M, Holtz ML, Matherly S, Lee H, Osman M, Siddiqui MS, Fuchs M, Puri P, Sikaroodi M, Gillevet PM. Bajaj JS, et al. Hepatology. 2019 Nov;70(5):1690-1703. doi: 10.1002/hep.30690. Epub 2019 Jun 18. Hepatology. 2019. PMID: 31038755 Free PMC article. Clinical Trial. - Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax.
O'Leary JG, Rajender Reddy K, Tandon P, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Lai JC, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, Bajaj JS. O'Leary JG, et al. Dig Dis Sci. 2021 Oct;66(10):3612-3618. doi: 10.1007/s10620-020-06677-6. Epub 2020 Nov 13. Dig Dis Sci. 2021. PMID: 33185787 Free PMC article. - Relationship between Quality Practice Metrics and Treatment Outcomes in Hospitalized Cirrhotic Patients.
Munsakul N, Chalermsuksant N, Sethasine S. Munsakul N, et al. Asian Pac J Cancer Prev. 2024 Dec 1;25(12):4153-4159. doi: 10.31557/APJCP.2024.25.12.4153. Asian Pac J Cancer Prev. 2024. PMID: 39733404 Free PMC article.
References
- Fontanarosa PB, McNutt RA. Revisiting hospital readmissions. JAMA. 2013;309:398–400. - PubMed
- Benbassat J, Taragin M. Hospital readmissions as a measure of quality of health care: advantages and limitations. Arch Intern Med. 2000;160:1074–1081. - PubMed
- Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology. 2009;136:1134–1144. - PubMed
- Kanwal F, Volk M, Singal A, Angeli P, Talwalkar J. Improving quality of health care for patients with cirrhosis. Gastroenterology. 2014;147:1204–1207. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical